Index RUT P/E - EPS (ttm) -0.17 Insider Own 88.17% Shs Outstand 701.66M Perf Week 5.92%
Market Cap 3.26B Forward P/E - EPS next Y -0.28 Insider Trans 0.04% Shs Float 83.02M Perf Month 15.38%
Income -116.06M PEG - EPS next Q -0.06 Inst Own 4.75% Short Float 28.18% Perf Quarter 3.33%
Sales 0.00M P/S - EPS this Y 75.18% Inst Trans -29.20% Short Ratio 10.25 Perf Half Y 154.79%
Book/sh 0.06 P/B 73.83 EPS next Y -12.97% ROA -53.77% Short Interest 23.40M Perf Year 119.34%
Cash/sh 0.22 P/C 20.79 EPS next 5Y - ROE -130.63% 52W Range 1.50 - 5.39 Perf YTD 78.16%
Dividend Est. - P/FCF - EPS past 5Y - ROI -77.35% 52W High -13.73% Beta -1.26
Dividend TTM - Quick Ratio 6.97 Sales past 5Y -28.65% Gross Margin - 52W Low 210.00% ATR (14) 0.42
Dividend Ex-Date - Current Ratio 6.97 EPS Y/Y TTM 90.98% Oper. Margin 0.00% RSI (14) 56.91 Volatility 10.66% 9.43%
Employees 105 Debt/Eq 2.48 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.00 Target Price 7.50
Option/Short Yes / Yes LT Debt/Eq 2.39 EPS Q/Q 95.68% Payout - Rel Volume 0.78 Prev Close 4.78
Sales Surprise - EPS Surprise 0.00% Sales Q/Q - Earnings May 01 BMO Avg Volume 2.28M Price 4.65
SMA20 16.05% SMA50 13.97% SMA200 62.25% Trades
Volume 1,780,668 Change -2.72%
Date
Action
Analyst
Rating Change
Price Target Change
May-07-24 Initiated Citigroup
Buy
$7
Mar-26-24 Initiated Stifel
Buy
$8
Jun-28-18 Downgrade Janney
Buy → Neutral
May-02-18 Initiated Janney
Buy
Apr-12-18 Reiterated Needham
Buy
$30 → $27
Feb-13-18 Initiated BTIG Research
Buy
$33
Jan-04-18 Initiated SunTrust
Buy
$24
Dec-01-17 Resumed H.C. Wainwright
Buy
$16
Nov-16-16 Reiterated RBC Capital Mkts
Outperform
$26 → $29
Oct-05-16 Reiterated Needham
Buy
$22 → $30
Sep-16-16 Initiated H.C. Wainwright
Buy
$26
Mar-30-15 Initiated Oppenheimer
Outperform
$28
Mar-30-15 Initiated Needham
Buy
$22
Show Previous Ratings
May-02-24 11:42AM
03:15AM
12:00AM
(Thomson Reuters StreetEvents)
May-01-24 11:55AM
07:00AM
04:30PM
Loading…
Apr-24-24 04:30PM
Apr-11-24 04:30PM
Apr-10-24 07:00AM
Apr-09-24 04:18PM
04:05PM
Apr-02-24 05:41PM
Mar-29-24 05:43PM
01:35PM
Mar-22-24 07:00AM
Mar-19-24 09:32AM
07:00AM
Loading…
Mar-14-24 07:00AM
Mar-05-24 07:00AM
Feb-21-24 08:53AM
01:56AM
(Thomson Reuters StreetEvents)
Feb-20-24 08:31AM
07:00AM
Feb-14-24 10:29AM
07:00AM
Feb-07-24 07:00AM
Jan-08-24 09:00AM
Jan-03-24 07:30AM
Nov-08-23 12:27PM
Nov-07-23 09:07AM
07:00AM
Nov-02-23 04:41PM
08:00AM
Loading…
08:00AM
Oct-31-23 08:00AM
Oct-26-23 08:00AM
Oct-19-23 08:00AM
Oct-16-23 11:01PM
07:00AM
Sep-29-23 12:43PM
Aug-09-23 10:19PM
(Thomson Reuters StreetEvents) +10.86%
07:00AM
Aug-02-23 08:00AM
Jul-11-23 11:48AM
Jun-04-23 08:00AM
Jun-01-23 07:30AM
May-22-23 09:30AM
May-18-23 09:46AM
May-16-23 01:21PM
11:44AM
May-11-23 11:18PM
(Thomson Reuters StreetEvents) -9.20%
12:20PM
07:30AM
May-09-23 07:30AM
May-05-23 05:08PM
May-03-23 08:30AM
Mar-09-23 03:42PM
07:30AM
Mar-03-23 08:00AM
Feb-23-23 08:00AM
Feb-01-23 10:25AM
Jan-30-23 08:00AM
Jan-20-23 08:00AM
Jan-05-23 09:59AM
07:00AM
Dec-30-22 01:25PM
Dec-09-22 08:27AM
Dec-08-22 04:45PM
Dec-06-22 09:54AM
07:30AM
Nov-17-22 04:15PM
Nov-12-22 07:10AM
Nov-09-22 08:30AM
Oct-20-22 05:15PM
Oct-18-22 08:16AM
Oct-13-22 08:00AM
Oct-04-22 11:49AM
Oct-03-22 04:37PM
Sep-12-22 09:17AM
Aug-22-22 01:16PM
Aug-20-22 08:37AM
Aug-19-22 11:58AM
Aug-11-22 08:00AM
Aug-09-22 01:37PM
Aug-02-22 09:25AM
Jul-26-22 04:15PM
Jul-18-22 04:05PM
Jul-14-22 11:35AM
08:30AM
Jun-22-22 04:30PM
Jun-03-22 08:30AM
Jun-01-22 08:30AM
May-11-22 04:30PM
May-08-22 09:44AM
Apr-10-22 08:36AM
Mar-17-22 04:14PM
Feb-24-22 04:51AM
(Simply Wall St.) +18.84%
Feb-09-22 08:00AM
Jan-25-22 07:30AM
Jan-10-22 08:00AM
Jan-05-22 07:30AM
Dec-31-21 02:30PM
Dec-28-21 04:04PM
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Zanganeh Mahkam Chief Executive Officer Mar 27 '24 Buy 3.72 54,321 201,874 24,923,800 Mar 27 08:28 PM Zanganeh Mahkam Chief Executive Officer Mar 27 '24 Buy 3.72 26,000 96,720 520,814 Mar 27 08:28 PM Dhingra Ankur Chief Financial Officer Mar 26 '24 Buy 3.75 100,000 375,000 354,958 Mar 27 08:27 PM Zanganeh Mahkam Chief Executive Officer Mar 26 '24 Buy 3.75 30,000 112,500 30,000 Mar 27 08:28 PM Dhingra Ankur Chief Financial Officer Dec 13 '23 Buy 2.17 20,400 44,254 254,958 Dec 13 04:49 PM Zanganeh Mahkam Chief Executive Officer Dec 12 '23 Buy 2.07 5,000 10,350 494,814 Dec 13 05:11 PM Soni Manmeet Singh Chief Operating Officer Oct 13 '23 Buy 1.68 2,976,190 4,999,999 2,976,190 Oct 16 04:06 PM
Index RUT P/E - EPS (ttm) -0.82 Insider Own 70.66% Shs Outstand 55.14M Perf Week -4.73%
Market Cap 411.46M Forward P/E - EPS next Y - Insider Trans 2.79% Shs Float 16.20M Perf Month 2.62%
Income -42.55M PEG - EPS next Q - Inst Own 8.33% Short Float 17.42% Perf Quarter -11.10%
Sales 0.00M P/S - EPS this Y - Inst Trans -15.31% Short Ratio 16.81 Perf Half Y 46.37%
Book/sh 0.66 P/B 11.34 EPS next Y - ROA -71.28% Short Interest 2.82M Perf Year -10.24%
Cash/sh 0.63 P/C 11.80 EPS next 5Y - ROE -332.14% 52W Range 3.78 - 13.62 Perf YTD -39.13%
Dividend Est. - P/FCF - EPS past 5Y 16.76% ROI -96.51% 52W High -45.30% Beta 1.64
Dividend TTM - Quick Ratio 7.06 Sales past 5Y -30.13% Gross Margin -4734.38% 52W Low 97.09% ATR (14) 0.59
Dividend Ex-Date - Current Ratio 7.06 EPS Y/Y TTM 43.33% Oper. Margin 0.00% RSI (14) 47.97 Volatility 8.61% 7.64%
Employees 56 Debt/Eq 0.25 Sales Y/Y TTM -100.00% Profit Margin - Recom 3.00 Target Price 5.00
Option/Short Yes / Yes LT Debt/Eq 0.21 EPS Q/Q 29.91% Payout - Rel Volume 0.90 Prev Close 6.95
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings May 07 AMC Avg Volume 167.88K Price 7.45
SMA20 1.66% SMA50 -10.49% SMA200 -0.26% Trades
Volume 150,500 Change 7.19%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-27-21 Initiated Stephens
Overweight
$28
Mar-11-21 Initiated Maxim Group
Buy
$40
Jan-26-21 Reiterated H.C. Wainwright
Buy
$16 → $40
May-12-20 Upgrade H.C. Wainwright
Neutral → Buy
$6 → $16
Feb-14-20 Downgrade H.C. Wainwright
Buy → Neutral
$26 → $6
Feb-25-19 Initiated H.C. Wainwright
Buy
$27
May-09-24 08:00AM
May-08-24 06:06AM
(Thomson Reuters StreetEvents) -9.21%
03:56AM
May-07-24 09:56PM
05:45PM
04:05PM
Loading…
04:05PM
May-02-24 08:00AM
Apr-28-24 11:59AM
Apr-24-24 04:05PM
Apr-01-24 04:19PM
Mar-29-24 06:30AM
(Thomson Reuters StreetEvents)
Mar-28-24 10:53PM
05:51PM
04:12PM
04:10PM
04:05PM
Loading…
Mar-14-24 04:05PM
Mar-08-24 01:17PM
Feb-14-24 08:00AM
Jan-31-24 08:00AM
Jan-02-24 08:00AM
Dec-20-23 08:00AM
Nov-21-23 08:00AM
Nov-15-23 04:05PM
Nov-14-23 12:52PM
02:15AM
(Thomson Reuters StreetEvents)
Nov-13-23 11:13AM
08:00AM
Nov-10-23 04:56PM
Oct-30-23 04:05PM
Oct-24-23 08:00AM
08:00AM
Loading…
Oct-02-23 08:00AM
Sep-29-23 08:00AM
Sep-27-23 08:00AM
Sep-07-23 04:05PM
Aug-24-23 04:05PM
Aug-17-23 09:31AM
Aug-11-23 06:28AM
(Thomson Reuters StreetEvents) +5.56%
Aug-10-23 04:05PM
Jul-30-23 09:35AM
Jul-27-23 04:05PM
May-22-23 09:30AM
May-18-23 07:00AM
May-16-23 12:01PM
May-12-23 07:43AM
(Thomson Reuters StreetEvents) +6.31%
May-11-23 04:05PM
May-10-23 09:29AM
May-03-23 08:00AM
May-01-23 08:00AM
Apr-27-23 04:05PM
Apr-20-23 06:04AM
Apr-05-23 07:46PM
Mar-30-23 04:05PM
Mar-10-23 08:30AM
Mar-02-23 04:05PM
Feb-02-23 08:00AM
Dec-10-22 07:24AM
Nov-10-22 04:05PM
Oct-27-22 04:05PM
Oct-14-22 06:17AM
Oct-06-22 08:00AM
Oct-01-22 08:50AM
Sep-26-22 10:00AM
08:00AM
Sep-21-22 10:03AM
Sep-20-22 04:26PM
Aug-10-22 05:25PM
04:05PM
Aug-04-22 08:00AM
Jul-27-22 04:05PM
Jun-16-22 04:15PM
Jun-09-22 04:43PM
Jun-03-22 08:00AM
May-19-22 08:00AM
May-13-22 01:44PM
(American City Business Journals) +14.86%
May-11-22 06:05PM
04:05PM
May-04-22 08:00AM
Apr-28-22 08:00AM
Apr-26-22 08:00AM
Apr-14-22 04:05PM
Mar-31-22 05:25PM
04:05PM
Mar-21-22 04:05PM
Mar-17-22 06:57AM
Feb-15-22 08:00AM
Feb-08-22 12:37PM
08:45AM
Feb-01-22 04:05PM
Jan-11-22 07:00AM
Dec-28-21 02:38AM
Dec-17-21 09:20AM
Nov-25-21 10:00AM
Nov-18-21 04:05PM
Nov-15-21 04:05PM
Nov-04-21 04:05PM
Nov-02-21 04:05PM
Oct-05-21 08:00AM
Sep-02-21 04:05PM
12:43PM
Aug-19-21 04:05PM
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DUGGAN ROBERT W Director Dec 12 '23 Buy 9.15 17,999 164,691 36,984,179 Dec 14 07:37 PM DUGGAN ROBERT W Director Dec 11 '23 Buy 9.36 90,118 843,504 36,966,180 Dec 13 06:03 PM DUGGAN ROBERT W Director Dec 08 '23 Buy 9.54 116,656 1,112,898 36,876,062 Dec 12 07:28 PM DUGGAN ROBERT W Director Dec 07 '23 Buy 9.19 74,852 687,890 36,759,406 Dec 11 08:13 PM DUGGAN ROBERT W Director Dec 06 '23 Option Exercise 5.95 9,933 59,101 36,601,741 Dec 08 07:38 PM DUGGAN ROBERT W Director Dec 06 '23 Buy 9.06 82,813 750,286 36,684,554 Dec 08 07:38 PM DUGGAN ROBERT W Director Dec 05 '23 Buy 9.34 66,021 616,636 351,565 Dec 07 08:34 PM DUGGAN ROBERT W Director Dec 04 '23 Option Exercise 10.66 40,347 430,099 36,591,808 Dec 06 07:54 PM DUGGAN ROBERT W Director Dec 04 '23 Buy 10.38 27,000 280,260 285,544 Dec 06 07:54 PM DUGGAN ROBERT W Director Dec 01 '23 Buy 9.07 45,600 413,592 258,544 Dec 05 08:31 PM DUGGAN ROBERT W Director Nov 30 '23 Buy 9.06 152,944 1,385,673 212,944 Dec 04 07:37 PM DUGGAN ROBERT W Director Nov 29 '23 Option Exercise 5.95 1,667 9,919 36,392,861 Dec 01 07:36 PM DUGGAN ROBERT W Director Nov 29 '23 Buy 9.44 158,600 1,497,184 36,551,461 Dec 01 07:36 PM DUGGAN ROBERT W Director Nov 29 '23 Buy 9.21 60,000 552,600 60,000 Dec 01 07:36 PM DUGGAN ROBERT W Director Nov 28 '23 Buy 8.98 124,397 1,117,085 36,391,194 Nov 30 07:25 PM DUGGAN ROBERT W Director Nov 17 '23 Buy 6.10 20,241 123,470 36,266,797 Nov 20 08:56 PM Danahy Kevin Patrick Chief Executive Officer Nov 16 '23 Buy 6.52 5,393 35,156 35,887 Nov 17 09:11 AM Levinson Mitchell E. Chief Strategy Officer Nov 15 '23 Buy 5.91 13,539 80,058 9,135 Nov 17 09:10 AM Levinson Mitchell E. Chief Strategy Officer Nov 15 '23 Buy 5.87 4,261 25,033 73,027 Nov 17 09:10 AM Zanganeh Mahkam Director Nov 13 '23 Option Exercise 2.14 76,075 162,800 604,911 Nov 15 05:37 PM DUGGAN ROBERT W Director Nov 07 '23 Option Exercise 5.95 13,265 78,927 36,246,556 Nov 09 06:32 PM DUGGAN ROBERT W Director Aug 25 '23 Option Exercise 5.95 1,667 9,919 36,233,291 Aug 28 08:08 PM DUGGAN ROBERT W Director Jul 25 '23 Option Exercise 5.95 1,667 9,919 36,231,624 Jul 27 09:09 AM DUGGAN ROBERT W Director Jul 07 '23 Option Exercise 2.23 67,133 150,012 36,229,957 Jul 07 06:26 PM DUGGAN ROBERT W Director Jul 05 '23 Option Exercise 2.14 65,000 139,100 36,162,824 Jul 07 06:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
